纤溶酶原激活物抑制剂-1抑制作用——心血管保护的另一种治疗选择
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.
作者信息
Baluta Monica Mariana, Vintila Marius Marcian
机构信息
Department of Cardiology, "St Pantelimon" Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
出版信息
Maedica (Bucur). 2015 Jun;10(2):147-152.
Abstract
Current research suggest that plasminogen activator inhibitor type 1 (PAI-1) is an important contributor to a number of disease processes. The aim of the current paper is to emphasize the deleterious effects of PAI-1 on cardiovascular diseases development and progression. The plasminogen system is known by its role in hemostasis and thrombosis regulation. Lifestyle changes and pharmacological treatment can regulate PAI-1 levels and functions. Some pharmacologic agents currently used in the management of atherosclerosis and its complications can counteract the deleterious effects of PAI-1.
摘要
目前的研究表明，1型纤溶酶原激活物抑制剂（PAI-1）是许多疾病进程的重要促成因素。本文的目的是强调PAI-1对心血管疾病发生和发展的有害影响。纤溶酶原系统因其在止血和血栓形成调节中的作用而为人所知。生活方式的改变和药物治疗可以调节PAI-1的水平和功能。目前用于治疗动脉粥样硬化及其并发症的一些药物可以抵消PAI-1的有害影响。
相似文献
1
PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection.纤溶酶原激活物抑制剂-1抑制作用——心血管保护的另一种治疗选择
Maedica (Bucur). 2015 Jun;10(2):147-152.
2
Use of mouse models to study plasminogen activator inhibitor-1.使用小鼠模型研究纤溶酶原激活物抑制剂-1。
Methods Enzymol. 2011;499:77-104. doi: 10.1016/B978-0-12-386471-0.00005-5.
3
Plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1
Curr Med Chem. 2004 Sep;11(17):2323-34. doi: 10.2174/0929867043364595.
4
Functional stability of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1的功能稳定性
ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15.
5
Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases.纤溶酶原激活物抑制剂-1 的特定化学抑制剂在心血管疾病中的作用。
Expert Opin Investig Drugs. 2011 Feb;20(2):255-64. doi: 10.1517/13543784.2011.546784. Epub 2011 Jan 3.
6
No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.在年轻女性摄入避孕类固醇之前及期间，胰岛素原和胰岛素对血浆1型纤溶酶原激活物抑制剂及组织型纤溶酶原激活物水平无影响。
Metabolism. 1996 Jul;45(7):833-7. doi: 10.1016/s0026-0495(96)90155-9.
7
Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.纤溶酶原激活物抑制剂-1抑制特性的中和作用：两种不同机制的鉴定。
Biochim Biophys Acta. 1997 Feb 8;1337(2):257-66. doi: 10.1016/s0167-4838(96)00173-2.
8
PAI-1, progress in understanding the clinical problem and its aetiology.PAI-1，对临床问题及其病因的认识进展。
Br J Haematol. 2012 May;157(3):291-8. doi: 10.1111/j.1365-2141.2012.09074.x. Epub 2012 Feb 24.
9
The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.PAI-1 的生物化学、生理学和病理学作用，以及体内抑制 PAI-1 的要求。
Thromb Res. 2012 Oct;130(4):576-85. doi: 10.1016/j.thromres.2012.06.023. Epub 2012 Jul 15.
引用本文的文献
1
The effects of resistance training on cardiovascular factors and anti-inflammation in diabetic rats.抗阻训练对糖尿病大鼠心血管因素及抗炎作用的影响
Heliyon. 2024 Aug 28;10(17):e37081. doi: 10.1016/j.heliyon.2024.e37081. eCollection 2024 Sep 15.
2
Identification and validation of as a prognostic and immunological biomarker in pan-cancer and in ccRCC.作为泛癌和肾透明细胞癌（ccRCC）中一种预后和免疫生物标志物的鉴定与验证
Front Pharmacol. 2023 Aug 23;14:1213891. doi: 10.3389/fphar.2023.1213891. eCollection 2023.
3
assessment of histotripsy-induced changes in catheter-directed thrombolytic delivery.组织超声碎裂术对导管定向溶栓给药影响的评估
Front Physiol. 2023 Jun 28;14:1225804. doi: 10.3389/fphys.2023.1225804. eCollection 2023.
4
Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi.评估静脉血栓的组织学特征、影像学标志物和 rt-PA 敏感性。
Sci Rep. 2021 Nov 23;11(1):22805. doi: 10.1038/s41598-021-02030-7.
5
PTSD as an Endothelial Disease: Insights From COVID-19.创伤后应激障碍作为一种内皮疾病：来自新冠疫情的见解
Front Cell Neurosci. 2021 Oct 29;15:770387. doi: 10.3389/fncel.2021.770387. eCollection 2021.
6
Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice.橙皮素对高胆固醇饮食喂养小鼠改善高胆固醇血症和非酒精性脂肪性肝病的疗效。
Nutr Res Pract. 2021 Aug;15(4):431-443. doi: 10.4162/nrp.2021.15.4.431. Epub 2021 Mar 11.
7
PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.PAI-1 在糖尿病中的作用：病理生理学及作为治疗靶点的角色。
Int J Mol Sci. 2021 Mar 20;22(6):3170. doi: 10.3390/ijms22063170.
8
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?纤溶酶原激活物抑制剂-1 的综述及其（病理）生理学作用：靶向还是不靶向？
Int J Mol Sci. 2021 Mar 8;22(5):2721. doi: 10.3390/ijms22052721.
9
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1：纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
10
RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis.犬原发性免疫介导性溶血性贫血（IMHA）全血 RNA 测序揭示疾病发病机制的新见解。
PLoS One. 2020 Oct 22;15(10):e0240975. doi: 10.1371/journal.pone.0240975. eCollection 2020.
本文引用的文献
1
Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes.肥胖个体血浆中鞘氨醇-1-磷酸水平升高及其在脂肪细胞中增加纤溶酶原激活物抑制剂-1表达的能力。
Coron Artery Dis. 2013 Dec;24(8):642-50. doi: 10.1097/MCA.0000000000000033.
2
Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle.人类的生物钟系统导致促血栓形成的纤溶酶原激活物抑制剂-1（PAI-1）在早晨达到峰值，而与睡眠/觉醒周期无关。
Blood. 2014 Jan 23;123(4):590-3. doi: 10.1182/blood-2013-07-517060. Epub 2013 Nov 7.
3
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.纤溶酶原激活物抑制剂-1 拮抗剂 TM5441 可减轻 Nω-硝基-L-精氨酸甲酯诱导的高血压和血管衰老。
Circulation. 2013 Nov 19;128(21):2318-24. doi: 10.1161/CIRCULATIONAHA.113.003192. Epub 2013 Oct 3.
4
Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?纤溶酶原激活物抑制剂-1：高血压的新型治疗靶点？
Circulation. 2013 Nov 19;128(21):2286-8. doi: 10.1161/CIRCULATIONAHA.113.006321. Epub 2013 Oct 3.
5
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.纤溶酶原激活物抑制剂-1 4G/5G多态性与2型糖尿病风险相关。
Int J Clin Exp Med. 2013 Sep 1;6(8):632-40. eCollection 2013.
6
7
Global gene expression profiling in PAI-1 knockout murine heart and kidney: molecular basis of cardiac-selective fibrosis.PAI-1 基因敲除鼠心肝基因表达谱分析：心肌选择性纤维化的分子基础
PLoS One. 2013 May 28;8(5):e63825. doi: 10.1371/journal.pone.0063825. Print 2013.
8
PAI-1 and diabetes: a journey from the bench to the bedside.纤溶酶原激活物抑制剂-1与糖尿病：从实验室到临床的历程
Diabetes Care. 2012 Oct;35(10):1961-7. doi: 10.2337/dc12-0638.
9
Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.纤溶酶原激活物抑制剂-1 与心血管风险因素在心血管风险在年轻芬兰人研究中的健康年轻成年人相关联。
Atherosclerosis. 2012 Sep;224(1):208-12. doi: 10.1016/j.atherosclerosis.2012.06.062. Epub 2012 Jul 16.
10
The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.PAI-1 的生物化学、生理学和病理学作用，以及体内抑制 PAI-1 的要求。
Thromb Res. 2012 Oct;130(4):576-85. doi: 10.1016/j.thromres.2012.06.023. Epub 2012 Jul 15.
Zotero 插件